BFC Planning’s Teva Pharmaceutical Industries TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$190K Sell
4,789
-200
-4% -$7.15K 0.01% 951
2026
Q2
$169K Sell
4,989
-3,190
-39% -$106K 0.01% 1002
2026
Q1
$246K Sell
8,179
-83
-1% -$2.67K 0.01% 800
2025
Q4
$258K Buy
8,262
+4,842
+142% +$119K 0.01% 771
2025
Q3
$69.1K Buy
+3,420
New +$60.1K 0.01% 1055
2025
Q2
– Sell
-9,531
Closed -$146K – 2844
2025
Q1
$146K Buy
9,531
+16
+0.2% +$286 0.01% 729
2024
Q4
$210K Buy
9,515
+3,125
+49% +$56.9K 0.02% 593
2024
Q3
$115K Buy
+6,390
New +$112K 0.01% 819

Other funds holding TEVA

BFC Planning's TEVA Position: Q3 2026 in Review

BFC Planning reduced its Teva Pharmaceutical Industries (TEVA) stake by 4% in Q3 2026, selling an estimated $7.15K and leaving 4,789 shares worth $190K. The position accounts for 0.01% of the portfolio, ranked #951.

BFC Planning first reported a position in TEVA in Q3 2024 and has held it in 8 quarters since. The position peaked at $258K in Q4 2025. 486 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • BFC Planning held 4,789 shares of Teva Pharmaceutical Industries worth $190K as of Q3 2026.
  • BFC Planning sold 200 Teva Pharmaceutical Industries shares in Q3 2026, an estimated $7.15K.
  • Teva Pharmaceutical Industries made up 0.01% of BFC Planning's portfolio in Q3 2026, its #951 holding.
  • BFC Planning first reported a position in Teva Pharmaceutical Industries in Q3 2024 and has held it in 8 quarters since.
  • BFC Planning's Teva Pharmaceutical Industries position peaked at $258K in Q4 2025.
  • 486 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.